Early Translational Research


Published on

June Lee, MD, Director of CTSI's Early Translational Research program, presents the goals and vision for the program. Learn more about June Lee at UCSF Profiles http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&Person=5208624

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • Thank you for the opportunity to share with you some of my preliminary thoughts and plans in early translational research at UCSF.
  • I have put together this framework to help me to simplify and think through the processses in translational research. And this has been useful to me in identifying the key gaps and potential needs. We have what is called early or T1 and later T2 translational research. Under T1, the work of translating science to invention/discovery occurs. Here, I will use the term invention to be synonymous with patent filing while acknowledging that there are discoveries that are not filable which can result in development of products that impact health. Under the T1 umbrella is also where this invention/discovery gets translated to a product that then can be used to impact health and to modify outcomes. I will use the term product to refer to a therapeutic/diagnostic/device/or an entity that can then be used for health benefit. This process is not quite as linear as this graphic would suggest. In an ideal world and in reality, there is feedback from the bedside to bench, from community to bedside and community to bench which informs the science (many would argue we can do better in that regard). In terms of where the resources and focus for the work at the various stages has traditionally been, academia has focused more on the science and discovery. Once there is an invention, start up companies moved the work along towards creating a product. At some point in this continuum, larger companies/pharmas then became involved as strategic partners or through acquisition. I should also mention that large pharma companies also invested significantly into in-house science and discovery work in the past. All analysis would indicate that this investment has been costly and not nearly as productive as hoped for. More recently, esource gaps have been growing. Venture funding for starting up and sustaining biotech/startups is becoming more scarce and the high failure rate of inventions/discoveries in the later phases of development among other reasons have led to large companies/ pharmas being less willing to take on molecules that others have developed at high valuations until substantial development has taken place (reducing the risk that lies ahead). Because internal R& D as well as startups/biotech have become a less reliable source for pipeline, large pharma/companies have been making a concerted effort at reaching directly into academia to get engaged early with the science and to populate, at least in part, their development pipeline in this mechanism. And of course, funding for academic research has been more challenging than ever before. And with the gaps in translational research widening, more is expected with less. In that regard, this new paradigm in which pharma is actively looking to invest in academia and to partner with academia is an opportunity.
  • One of the programs T1 traslational catalyst award is a program which was initiated a year and a half ago to address the gap of invention to product. It is intended to identify projects with diagnostic, device, or therapeutic potential The program then provides a customized panel review and in some cases, provided a customized consultation award for the program.
  • My thoughts on this early assessment are that the award program only helped to identify a small proportion of the science and invention here at UCSF. And while it’s important to identify the inventions that are ready for support in becoming products, it’s perhaps equally as important to identify the early program to help science to become inventions. And that providing access to the customized consulting and small pilot grants can be a mechanism by which we can identify some of the promising earlier science.
  • We are starting the discuss how we might be able to offer the components of T1 Catalyst award thought to be most valuable to more investigators…in particular the pilot grants and the consultation program. Preliminary thoughts around this is that we would create a more comprehensive T1 transalational catalyst program which would include the T1 catalyst award but would also include a freestanding consultation program and pilot-micro grants program for investigators whose programs are less mature and might need a more limited one time consult or a small pilot grant to do that experiment which then can help determine human relevance for the program. Both the consultation and micro grants program would be designed to be minimal process with a quick turn-around on the order of 1-2 wks for decision. Stay tuned for more on this. This can also then be used as a mechanism by which we identify science which have the potential to become inventions. In that way, it can also serve as a funnel to identify programs that can then apply for a full T1 Catalyst Award.
  • Early translational research is a complex, multidisciplinary, and in places capital intensive endeavor. The goal is to build innovative partnerships that is fit for purpose in such a way that the scientists at UCSF can continue to do what they do best while leveraging the capabilities that reside in the resources that surround us in the industry and other partners/ collaborators. This might mean that we enter into a collaboration that is more of a co-development model in the way the Pfizer CTI program is set up. This might mean we engage the a venture company to help us get a company started as QB3 has done with great success. We are in active discussions with many of these entities to set up partnerships that are fit for purpose. UCSF/Academia Cutting edge science Deep subject matter expertise and experts Industry partners Development experience Process capabilities Access to resources Potential source for funding
  • Early Translational Research

    1. 1. CTSI SLG November 7, 2011 Early Translational Research June Lee, MD
    2. 2. Translational research Early (T1) Late ( T2) Bench Bedside Community Outcomes/ Impact Better Health Academia Start up company/ biotech Large pharma/company Academia Start up company/ biotech Large pharma/company
    3. 3. T1 Translational Catalyst Award <ul><li>Identify the best projects </li></ul><ul><ul><li>Diagnostics, devices, or therapeutics </li></ul></ul><ul><li>Bring in missing pieces </li></ul><ul><ul><li>Panels include people from industry and academics </li></ul></ul><ul><ul><li>Panels review and provide individualized feedback </li></ul></ul><ul><li>Leverage limited resources </li></ul><ul><ul><li>Identify partnerships if appropriate </li></ul></ul><ul><li>Feedback </li></ul><ul><ul><li>Pilot grants helped advance programs </li></ul></ul><ul><ul><li>Customized consulting service very useful </li></ul></ul>
    4. 4. T1 Catalyst Award program assessment <ul><li>Status </li></ul><ul><ul><li>In our 4 th cycle of funding </li></ul></ul><ul><ul><li>Number of proposals submitted increased substantially </li></ul></ul><ul><ul><li>Changed the review process to include multiple specialized tracks </li></ul></ul><ul><ul><ul><li>Therapeutics (13 proposals) </li></ul></ul></ul><ul><ul><ul><li>Diagnostics (8 proposals) </li></ul></ul></ul><ul><ul><ul><li>Devices (4 proposals) </li></ul></ul></ul><ul><ul><ul><li>mHealth (8 proposals) </li></ul></ul></ul><ul><ul><ul><li>Orphan/ rare diseases (TBA) </li></ul></ul></ul>
    5. 5. T1 Catalyst Panels/ Consultations <ul><li>Consultation panel comprised of: </li></ul><ul><ul><li>Faculty </li></ul></ul><ul><ul><li>Industry experts (Approximately 80% volunteers) </li></ul></ul><ul><ul><ul><li>Drug/Device/Diagnostics development experts </li></ul></ul></ul><ul><ul><ul><li>IP attorneys </li></ul></ul></ul><ul><ul><ul><li>Venture capitalists </li></ul></ul></ul><ul><ul><ul><li>Experienced bioentrepreneurs </li></ul></ul></ul><ul><ul><li>OTM representative </li></ul></ul><ul><ul><li>QB3 representative </li></ul></ul>
    6. 6. Consultation awards <ul><li>Offered to approximately 50% of applicants </li></ul><ul><li>Average award value $2K-$5K </li></ul><ul><li>Pilot award and 100K award recipients will be determined in February </li></ul>
    7. 7. Other key activities in T1 Catalyst Program <ul><li>Deploying the consultation service to UCSF investigators beyond the T1 Catalyst Award participants </li></ul><ul><ul><li>In collaboration with OTM </li></ul></ul><ul><li>Enhance the consultant panel </li></ul><ul><li>Identifying additional sources of funding </li></ul><ul><ul><li>Pharma partners </li></ul></ul><ul><ul><li>Entrepreneurs/VCs </li></ul></ul>
    8. 8. T1 translational catalyst program Identify & Enable Science  Invention Invention  Product Gap: Science to Invention, Invention to Product
    9. 9. Translational research in drug development <ul><li>Unmet medical </li></ul><ul><li>need/potential clinical indication(s) </li></ul><ul><li>~18 months </li></ul><ul><li>DISCOVERY </li></ul><ul><li>ESR </li></ul><ul><li>LSR </li></ul><ul><li>ED </li></ul><ul><li>ECD (Ph I/II) </li></ul><ul><li>IND submission and clearance </li></ul>
    10. 10. Early phase drug development activities <ul><li>Discovery/Early stage research/ Late stage research </li></ul><ul><ul><li>Target selection/validation </li></ul></ul><ul><ul><li>Proof of activity </li></ul></ul><ul><ul><li>Lead molecule optimization </li></ul></ul><ul><ul><li>Evaluation of unmet need </li></ul></ul><ul><ul><li>Define target candidate profile (TCP ) </li></ul></ul><ul><li>Late stage research/ Pre-early development </li></ul><ul><ul><li>Select lead molecule </li></ul></ul><ul><ul><li>Indication (s) selection </li></ul></ul><ul><ul><li>Define target product profile (TPP) </li></ul></ul><ul><li>Early Development </li></ul><ul><ul><li>Clinical manufacturing </li></ul></ul><ul><ul><li>IND enabling toxicology study </li></ul></ul><ul><ul><li>Regulatory filing strategy </li></ul></ul><ul><ul><li>Overall clinical development strategy </li></ul></ul>
    11. 12. Innovative partnerships <ul><li>Critical to extending the T1 translational capacity in academia </li></ul><ul><li>Non-traditional models and re-defining the boundaries of private/public partnerships </li></ul><ul><ul><li>Pharma/academia </li></ul></ul><ul><ul><li>Early stage investors (e.g. Venture capital) </li></ul></ul><ul><ul><li>Foundations and venture philanthropy </li></ul></ul><ul><ul><li>Others </li></ul></ul>